2.14  -0.03 (-1.38%)		01-26 16:00
Open: 2.15 High: 2.17 Volume: 723,696		Pre. Close: 2.17 Low: 2.1047 Market Cap: 602(M)

Short term
Mid term
Targets	6-month :	2.78	1-year :	3.02
Resists	First :	2.38	Second :	2.58
Pivot price	2.24
Supports	First :	2.05	Second :	1.71
MAs	MA(5) :	2.15	MA(20) :	2.25
	MA(100) :	2.54	MA(250) :	1.91
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	21.7	D(3) :	20.6
RSI	RSI(14): 42.6
52-week	High :	7.13	Low :	0.46

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PROK ] has closed above bottom band by 21.1%. Bollinger Bands are 47.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.17 - 2.19	2.19 - 2.2
Low:	2.08 - 2.09	2.09 - 2.1
Close:	2.12 - 2.14	2.14 - 2.16

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Thu, 15 Jan 2026
ProKidney (NASDAQ:PROK) Stock Price Down 5.5% - What's Next? - MarketBeat

Mon, 12 Jan 2026
ProKidney Corp Updates on Rilparencel and Phase 3 Trials - TradingView

Tue, 06 Jan 2026
ProKidney Corp. CEO Bruce Culleton to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Tue, 06 Jan 2026
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Tue, 06 Jan 2026
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Sat, 27 Dec 2025
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	142 (M)
Held by Insiders	9.327e+007 (%)
Held by Institutions	25.3 (%)
Shares Short	14,790 (K)
Shares Short P.Month	0 (K)

EPS	-1.6458e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-17 %
Return on Assets (ttm)	613.3 %
Return on Equity (ttm)	-25.9 %
Qtrly Rev. Growth	744000 %
Gross Profit (p.s.)	0
Sales Per Share	-22.98
EBITDA (p.s.)	408791
Qtrly Earnings Growth	-0.6 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-112 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.1
Price to Cash Flow	-0.53

Dividend	0
Forward Dividend	1.518e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.